Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 94 of 103, showing 5 Applications out of 512 total, starting on record 466, ending on 470

# Protocol No Study Title Investigator(s) & Site(s)

466.

ECCT/13/04/02  
    XANTUS EMEA-LA. Xarelto® on prevention of stroke and non-central nervous system systemic embolism in patients with non-valvular atrial fibrillation in Eastern EU, Middle East, Africa (EMEA) and Latin America (LATAM): A non-interventional study   
Principal Investigator(s)
1. Dr Charles Muthui Kariuki
Site(s) in Kenya
Nairobi Cardiovascular Clinic
 
View

467.

ECCT/13/04/08  
    Switching At Low HIV-1 RNA Into Fixed Dose Combinations   SALIF   Protocol Number: TMC278IFD3002 Amendment INT-1   
Principal Investigator(s)
1. Edwin Onyango WERE
2. Milton Tony OMONDI
3. Gina OUATTARA
4. Gaudensia Nzembi MUTUA
5. Reena SHAH
Site(s) in Kenya
1. Aga Khan University Hospital (Nairobi City county)
2. KEMRI/Walter-Reed Project Kombewa (Kisumu county)
3. Partners in Prevention (Uasin Gishu county)
4. Kenya AIDS Vaccine Initiative - KNH (Nairobi City county)
5. Kenya AIDS Vaccine Initiative - Kangemi (Nairobi City county)
 
View

468.

ECCT/16/07/01   VAC52150EBL4001
    A Multi-country, prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola Vaccines AD26.ZEBOV and or/ MVA-BN-Filo   
Principal Investigator(s)
1. Omu Anzala
Site(s) in Kenya
1. KAVI-Institute of Clinical Research (Nairobi City county)
2. Kenya medical Research Institute/Walter Reed Project Kombewa (Kisumu county)
3. Kenya medical Research Institute/Walter Reed Project Kombewa (Kericho county)
 
View

469.

ECCT/21/11/01   VAT 00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older   
Principal Investigator(s)
1. Walter Godfrey Jaoko
Site(s) in Kenya
1. Kenya Medical Research Institute (Kisumu county)
2. KEMRI/Walter Reed Project Research Center (Kericho county)
3. KEMRI/CCR Partners in Health R&D (PHRD) (Kiambu county)
4. KEMRI CMR (Kisumu county)
5. Kenya Medical Research Institute (Nairobi City county)
6. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center (Kisumu county)
7. Moi University Clinical Research Centre (Uasin Gishu county)
8. Aga Khan University Hospital (Nairobi City county)
9. KEMRI CCR-Butere County Hospital Site (Kakamega county)
10. Ganjoni Clinic (Mombasa county)
 
View

470.

ECCT/19/05/01   A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults
    A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults   
Principal Investigator(s)
1. Omu Anzala
Site(s) in Kenya
KAVI-ICR KNH SITE
 
View